Joseph Ciaffoni - Collegium Pharmaceutical COO, Executive Vice President
| COLL Stock | USD 29.66 1.32 4.26% |
President
Mr. Joseph J. Ciaffoni is the President, Chief Executive Officer, Director of Collegium Pharmaceutical Inc. Mr. Ciaffoni has served as our President and Chief Executive Officer since July 2018, and prior to that, served as our Executive Vice President and Chief Operating Officer since May 2017. Prior to joining us, Mr. Ciaffoni served as President, U.S. Branded Pharmaceuticals of Endo International plc, a specialty pharmaceutical company, from August 2016 to December 2016. Before that, from April 2012 to August 2016, Mr. Ciaffoni held various positions of increasing responsibility at Biogen Idec, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen Idec, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals from July 2008 to October 2010. Mr. Ciaffoni also previously served as Vice President, Sales for ScheringPlough from May 2004 to June 2008, where he was responsible for the cholesterol franchise, and has held several commercial leadership roles at SanofiSynthelabo from January 2002 to April 2004 and Novartis from January 1994 to December 2001 since 2018.
| Age | 53 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 100 Technology Center Drive, Stoughton, MA, United States, 02072 |
| Phone | 781 713 3699 |
| Web | https://www.collegiumpharma.com |
Joseph Ciaffoni Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Ciaffoni against Collegium Pharmaceutical stock is an integral part of due diligence when investing in Collegium Pharmaceutical. Joseph Ciaffoni insider activity provides valuable insight into whether Collegium Pharmaceutical is net buyers or sellers over its current business cycle. Note, Collegium Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Collegium Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Ciaffoni over six months ago Disposition of 26454 shares by Joseph Ciaffoni of Collegium Pharmaceutical at 21.34 subject to Rule 16b-3 |
Collegium Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0968 % which means that it generated a profit of $0.0968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4289 %, meaning that it created $0.4289 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.08 this year. Return On Capital Employed is expected to rise to 0.23 this year. At this time, Collegium Pharmaceutical's Return On Assets are quite stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| John Condon | Intracellular Th | N/A | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Jonathan Bendheim | Phibro Animal Health | 49 | |
| Michael Landine | Alkermes Plc | 70 | |
| Lisa Escudero | Phibro Animal Health | 63 | |
| Ganadhish Kamat | Dr Reddys Laboratories | 57 | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| Luis Aragon | Procaps Group SA | 61 | |
| David Gaffin | Alkermes Plc | 52 | |
| Mauricio Caballero | Procaps Group SA | 48 | |
| Mark Neumann | Intracellular Th | 62 | |
| Saumen Chakraborty | Dr Reddys Laboratories | 58 | |
| Robert Davis | Intracellular Th | 74 | |
| Stephen Carey | ANI Pharmaceuticals | 54 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Samson Li | Phibro Animal Health | 53 | |
| Kurt Knab | Evolus Inc | N/A | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Marcela Pagano | Procaps Group SA | 58 | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| Michael Olchaskey | Intracellular Th | N/A | |
Management Performance
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0968 |
Collegium Pharmaceutical Leadership Team
Elected by the shareholders, the Collegium Pharmaceutical's board of directors comprises two types of representatives: Collegium Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Collegium. The board's role is to monitor Collegium Pharmaceutical's management team and ensure that shareholders' interests are well served. Collegium Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Collegium Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bart Dunn, Executive Development | ||
| Scott Dreyer, Executive Vice President Chief Commercial Officer | ||
| Scott Sudduth, Head Operations | ||
| Christopher MD, Vice Relations | ||
| Shirley JD, General VP | ||
| RPh Pharm, Chairman, CoFounder | ||
| Marlo Manning, Head HR | ||
| Joseph Ciaffoni, COO, Executive Vice President | ||
| Colleen Tupper, Executive CFO | ||
| Alex Dasalla, Head Relations | ||
| Richard MD, Ex Officer | ||
| MD FAAFP, Executive Officer | ||
| Vikram Karnani, President CEO | ||
| Shirley Kuhlmann, Executive Vice President General Counsel, Secretary |
Collegium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Collegium Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0968 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 32.25 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 97.84 % | ||||
| Number Of Shares Shorted | 5.68 M | ||||
| Price To Earning | 28.80 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share | Quarterly Revenue Growth 0.165 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.